Recent Updates
Recently added Catalysts
ELDN Positive Sentiment

Second Xenotransplant with Gene-Edited Pig Kidney Performed at Mass General

Key Takeaway: Mass General has successfully performed its second xenotransplant using a gene-edited pig kidney. This groundbreaking procedure demonstrates significant advancements in organ transplantation, potentially improving patient outcomes. The use of genetically modified organs could address the ongoing shortage of human organ donors.
Price reaction · baseline $4.5 (2025-02-12 close) · hit after-hours · 4 other ELDN headline(s) in the window, move may be shared
day 0 close
-0.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Successful performance of second xenotransplant surgery.
  • Use of gene-edited pig kidney shows promising advancements.
  • Potential to transform organ transplantation and patient outcomes.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+90%
120-day peak, hindsight
Typical move
6.5%
average across 7 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
AT-1501
Phase 2 · Kidney Transplant Rejection

Full Press Release Details

Transforming Lives. One Organ at a Time.
• Overview Focus Patient Stories Clinical Trials In The News
• Science Mechanism of Action Pipeline Publications & Presentations In The News
• Team Overview Leadership Board of Directors
• Investors Overview News & Events Press Releases Events Publications & Presentations Corporate Governance Governance Overview Committee Composition Ethics Hotline Financials SEC Filings Stock Information Stock Quote & Chart Analyst Coverage Resources Investor FAQs Email Alerts Contact IR
• Culture/Careers Culture Careers
• Contact
• Focus
• Patient Stories
• Clinical Trials
• In The News
• Mechanism of Action
• Pipeline
• Publications & Presentations
• In The News
• Overview
• Leadership
• Board of Directors
• Overview
• News & Events Press Releases Events Publications & Presentations
• Corporate Governance Governance Overview Committee Composition Ethics Hotline
• Financials SEC Filings
• Stock Information Stock Quote & Chart Analyst Coverage
• Resources Investor FAQs Email Alerts Contact IR
• Press Releases
• Events
• Publications & Presentations
• Governance Overview
• Committee Composition
• Ethics Hotline
• SEC Filings
• Stock Quote & Chart
• Analyst Coverage
• Investor FAQs
• Email Alerts
• Contact IR
• Culture
• Careers
• Privacy Overview
• Necessary
• Analytics
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.

Frequently Asked Questions

What is xenotransplantation?

Xenotransplantation involves transplanting organs or tissues from one species to another.

What type of organ was transplanted?

A gene-edited pig kidney was transplanted in the recent procedure.

Where was the procedure performed?

The procedure was performed at Mass General Hospital.

Why is this procedure significant?

It addresses the shortage of human organ donors and could improve patient outcomes.

Last updated: Feb 12, 2025